{"entity":{"id":"paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004","kind":"paper","name":"Gallbladder cancer: lessons from a rare tumour","aka":[],"tldr":"A 2004 review arguing that gallbladder cancer, rare and little studied, is worth understanding because its mix of inherited risk, geography, female predominance, chronic inflammation and congenital anomalies is unusual among cancers.","summary":"Nature Reviews Cancer article stating that gallbladder cancer is a relatively rare malignancy about which knowledge is scant, and that its combination of predisposing factors (genetic predisposition, geographic distribution, female gender bias, chronic inflammation and congenital developmental abnormalities) makes it unique and informative for cancer pathogenesis generally. The authors argue that understanding how these risk factors contribute to the molecular basis of the disease is essential.","asOf":"2026-09-24","links":[{"label":"Nat Rev Cancer 2004","url":"https://doi.org/10.1038/nrc1429"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/15343276/"}],"tags":["gallbladder-evidence"],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-rare-cancers","b-funding-allocation"],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"journal":"Nature Reviews Cancer","year":2004,"doi":"10.1038/nrc1429","pmid":"15343276","authors":"Wistuba II, Gazdar AF.","paperType":"review","findings":["Describes gallbladder cancer as a relatively rare malignancy about which knowledge is scant (authors' words)."],"whatItMeans":"Two decades on, the disease is still described as understudied in the 2025 immunogenomics literature; the reasons (rarity in the countries that fund research, incidental diagnosis, pooling with bile duct cancer in trials) have not changed.","caveats":["Review from 2004; molecular detail is dated.","No new data."],"changedPractice":false},"route":"/key-papers/paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"bottleneck":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}],"journal":[{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/"}],"roadmap":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"}],"idea":[{"id":"idea-gbc-burden-to-funding-audit-and-dedicated-call","kind":"idea","name":"A burden-to-funding audit for gallbladder cancer and a dedicated research call","route":"/ideas/idea-gbc-burden-to-funding-audit-and-dedicated-call/"}]}}